Video

Dr. Verstovsek on the Different Phases of MPNs

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, the United Energy Resources, Inc. Professor of Medicine; director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms; and chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the different phases of myeloproliferative neoplasms (MPNs).

MPNs, such as myelofibrosis, are defined by the myeloid blasts found in the peripheral blood or bone marrow.

Notably, patients will not transition from chronic phase (<10% blasts) to blast phase (>20% blasts) overnight. Rather, this is a gradual process, says Verstovsek. During the accelerated phase, blasts range from 10% to 19%.

For patients in chronic phase, survival ranges from 5 to 7 years. In comparison, patients in accelerated phase and blast phase have survivals of 18 months and 6 months, respectively

Per the National Comprehensive Cancer Network guidelines, it’s of critical importance to intervene when blasts reach 10%, Verstovsek concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center